Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
71.22M | 69.30M | 58.45M | 41.42M | 29.46M | 18.21M | Gross Profit |
47.66M | 46.49M | 40.11M | 27.04M | 18.81M | 11.23M | EBIT |
-39.76M | -34.12M | -44.08M | -39.01M | -29.45M | -25.27M | EBITDA |
-37.31M | -31.68M | -40.63M | -39.06M | -29.14M | -24.70M | Net Income Common Stockholders |
-43.44M | -37.84M | -46.66M | -44.34M | -36.11M | -31.88M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
42.83M | 52.67M | 46.73M | 42.02M | 43.93M | 74.39M | Total Assets |
77.25M | 86.57M | 78.05M | 67.86M | 62.54M | 86.46M | Total Debt |
41.81M | 41.67M | 41.08M | 39.92M | 31.49M | 30.83M | Net Debt |
-1.03M | -11.00M | -5.65M | -2.10M | -12.44M | -43.57M | Total Liabilities |
59.13M | 58.11M | 59.17M | 53.55M | 42.45M | 37.43M | Stockholders Equity |
18.12M | 28.46M | 18.88M | 14.30M | 20.10M | 49.03M |
Cash Flow | Free Cash Flow | ||||
-37.65M | -42.58M | -41.47M | -42.62M | -31.06M | -24.62M | Operating Cash Flow |
-36.94M | -41.59M | -40.86M | -40.75M | -30.43M | -24.46M | Investing Cash Flow |
-107.00K | 4.45M | -599.00K | -1.87M | -627.00K | 9.12M | Financing Cash Flow |
42.88M | 43.06M | 46.27M | 40.85M | 585.00K | 44.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $103.29M | ― | -16.53% | ― | -4.15% | 3.49% | |
60 Neutral | $73.18M | ― | -267.29% | ― | 12.78% | 15.53% | |
58 Neutral | $76.98M | ― | -52.88% | ― | ― | 29.64% | |
58 Neutral | $39.85M | ― | -276.15% | ― | 41.54% | 42.59% | |
56 Neutral | $64.82M | ― | -130.26% | ― | -6.27% | 16.76% | |
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% | |
$43.24M | ― | -257.72% | ― | ― | ― |
On May 30, 2025, TELA Bio announced the resignation of Jeffrey Blizard from its Board of Directors, effective June 2, 2025, as he transitions to the role of President. This strategic leadership change is expected to enhance TELA Bio’s growth trajectory, with Blizard bringing extensive industry experience from his previous role at Abiomed, a Johnson & Johnson company. The appointment is seen as a significant step in strengthening the company’s executive team to drive commercial performance and value delivery to stakeholders.
The most recent analyst rating on (TELA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
On May 28, 2025, TELA Bio, Inc. held its Annual Meeting of Stockholders where several key proposals were approved. The stockholders voted to amend the 2019 Equity Incentive Plan by increasing the authorized shares by 3,500,000 and removing the ‘evergreen’ provision. Additionally, the election of Class III directors, the ratification of KPMG LLP as the independent public accountant, and the approval of executive compensation were confirmed. The amendment to the company’s Certificate of Incorporation to limit officer liability was also approved, reflecting strategic governance adjustments.
The most recent analyst rating on (TELA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
On May 8, 2025, TELA Bio reported its financial results for the first quarter of 2025, showing a revenue increase to $18.5 million, up 12% from the previous year. The growth was driven by increased demand for their OviTex products and the full U.S. commercial launch of larger-sized OviTex PRS. Despite the revenue growth, the company reported a net loss of $11.3 million, attributed to decreased gross margins and increased operating expenses. TELA Bio reiterated its full-year revenue guidance, expecting a 23% to 27% growth over 2024, and highlighted the optimization of its sales organization as a key factor in achieving new account wins and market penetration.
On March 20, 2025, TELA Bio reported its financial results for the fourth quarter and full year of 2024, showing a 19% revenue growth for the year, driven by increased demand for its OviTex and OviTex PRS products. Despite some disruptions affecting the fourth quarter, the company remains optimistic about capturing additional market share and restoring growth. TELA Bio also provided a revenue guidance for 2025, projecting growth of 23% to 27% over 2024, while maintaining operating expenses at the same level as the previous year.